Vanguard Group Inc. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Vanguard Group Inc. boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 0.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 523,165,127 shares of the biopharmaceutical company’s stock after purchasing an additional 4,629,976 shares during the quarter. Vanguard Group Inc. owned about 0.09% of Pfizer worth $13,257,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. William B. Walkup & Associates Inc. boosted its stake in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after buying an additional 454 shares during the period. Members Trust Co boosted its stake in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 467 shares during the period. Sutton Place Investors LLC boosted its stake in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 472 shares during the period. Bellevue Group AG boosted its stake in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock worth $3,756,000 after buying an additional 485 shares during the period. Finally, Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research note on Wednesday, April 30th. Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $28.28.

Check Out Our Latest Analysis on Pfizer

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.69 on Wednesday. The company has a market capitalization of $140.37 billion, a PE ratio of 17.89, a P/E/G ratio of 0.85 and a beta of 0.52. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a 50-day simple moving average of $24.39 and a two-hundred day simple moving average of $24.54. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s payout ratio is presently 124.64%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).